RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?

被引：27
作者：
Tesarova, P. [1 ,2 ]
Cabinakova, M. [1 ,2 ]
Mikulova, V. [2 ,3 ]
Zima, T. [2 ,3 ]
Kalousova, M. [2 ,3 ]
机构：
[1] Charles Univ Prague, Dept Oncol, Fac Med 1, Prague, Czech Republic
[2] Gen Univ Hosp, Prague, Czech Republic
[3] Charles Univ Prague, Inst Med Biochem & Lab Diagnost, Fac Med 1, Prague, Czech Republic
来源：
NEOPLASMA | 2015年 / 62卷 / 03期
关键词：
RAGE; cancer; HMGB1; S100; proteins; GLYCATION END-PRODUCTS; ALTERNATIVELY SPLICED RAGEV1; SOLUBLE FORM SRAGE; ENDPRODUCTS RAGE; MELANOMA GROWTH; RECEPTOR; EXPRESSION; RISK; POLYMORPHISM; AGES;
D O I：
10.4149/neo_2015_061
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Receptor for advanced glycation end products (RAGE) plays a central role in the regulation of tissue homeostasis, regeneration and resolution of inflammation, but under pathological conditions RAGE-mediated pathways may induce diminished apoptosis, but enhanced autophagy and cell necrosis. These mechanisms may contribute to malignant transformation, cancer progression and metastases. Soluble RAGE may bind natural RAGE ligands and counteract some of the RAGE-mediated effects. Activation of RAGE was demonstrated in different types of cancer (including colon, pancreatic and breast cancer). Expression of RAGE and serum levels of soluble RAGE may serve as cancer biomarkers and strategies aimed at interfering with RAGE signaling might be promising anticancer drugs.
引用
收藏
页码：353 / 364
页数：12
相关论文
共 78 条
[21]  
Jiao L, 2012, INT J MOL EPIDEMIOL, V3, P294
[22]   Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer [J].
Jiao, Li ;
Taylor, Philip R. ;
Weinstein, Stephanie J. ;
Graubard, Barry I. ;
Virtamo, Jarmo ;
Albanes, Demetrius ;
Stolzenberg-Solomon, Rachael Z. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (07) :1430-1438
[23]   Evidence That Serum Levels of the Soluble Receptor for Advanced Glycation End Products Are Inversely Associated with Pancreatic Cancer Risk: A Prospective Study [J].
Jiao, Li ;
Weinstein, Stephanie J. ;
Albanes, Demetrius ;
Taylor, Philip R. ;
Graubard, Barry I. ;
Virtamo, Jarmo ;
Stolzenberg-Solomon, Rachael Z. .
CANCER RESEARCH, 2011, 71 (10) :3582-3589
[24]   Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer [J].
Jing, R. ;
Cui, M. ;
Wang, J. ;
Wang, H. .
NEOPLASMA, 2010, 57 (01) :55-61
[25]   Tissue-Specific Expression Profiling of Receptor for Advanced Glycation End Products and Its Soluble Forms in Esophageal and Lung Cancer [J].
Jing, Rong-Rong ;
Cui, Ming ;
Sun, Bao-Lan ;
Yu, Juan ;
Wang, Hui-Min .
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2010, 14 (03) :355-361
[26]   Alternatively Spliced RAGEv1 Inhibits Tumorigenesis through Suppression of JNK Signaling [J].
Kalea, Anastasia Z. ;
See, Fiona ;
Harja, Evis ;
Arriero, Maria ;
Schmidt, Ann Marie ;
Hudson, Barry I. .
CANCER RESEARCH, 2010, 70 (13) :5628-5638
[27]   AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway [J].
Kang, Rui ;
Tang, Daolin ;
Lotze, Michael T. ;
Zeh, Herbert J., III .
AUTOPHAGY, 2012, 8 (06) :989-991
[28]   Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy [J].
Kohles, Nikolaus ;
Nagel, Dorothea ;
Juengst, Dietrich ;
Stieber, Petra ;
Holdenrieder, Stefan .
TUMOR BIOLOGY, 2012, 33 (06) :2401-2409
[29]   Analysis of AGE modified proteins and RAGE expression in HER2/neu negative invasive ductal carcinoma [J].
Korwar, Arvind M. ;
Bhonsle, Hemangi S. ;
Chougale, Ashok D. ;
Kote, Sachin S. ;
Gawai, Kachru R. ;
Ghole, Vikram S. ;
Koppikar, Chaitanyananda B. ;
Kulkarni, Mahesh J. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 419 (03) :490-494
[30]   The expression of HMGB1 protein and its receptor RAGE in human malignant tumors [J].
Kostova, Nora ;
Zlateva, Stanislava ;
Ugrinova, Iva ;
Pasheva, Evdokia .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2010, 337 (1-2) :251-258
12345678